DSEN ABSTRACT
Selective serotonin reuptake inhibitors (SSRI) and risks of fracture

Summary
In our analysis using data from a population-based cohort, SSRI/SNRI use was associated with increased risk of fragility fracture. After controlling for multiple risk factors, the adjusted hazard ratio for current SSRI/SNRI use was elevated (HR, 1.68; 95% CI, 1.32–2.14).

Key messages
Our results suggest an independent association between SSRI/SNRI use and subsequent fragility fracture. Given the high prevalence of antidepressants use, and the impact of fractures on the health, our findings may have a significant clinical impact.

What is the issue?
- Some antidepressants, such as selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs) may increase the risk of fractures.
- The rationale is that these drugs can increase the risk of falls and decrease bone mineral density.

What was the aim of the study?
- To evaluate whether antidepressant medication use is associated with fracture risk.

How was the study conducted?
- We used 10-year data from the Canadian Multicentre Osteoporosis Study (CaMos).
- Occurrence of fractures was assessed annually and drug exposure at 3 time points during the study period.
- Time to event analysis was used to assess the association between SSRI/SNRI use and time to first fragility fracture.

What did the study find?
- Among 6,645 selected participants, 978 experienced at least one fragility fracture.
- Current use of either SSRI/SNRI was associated with an increased risk of fragility fracture (HR, 1.68; 95% CI, 1.32–2.14).
- The results also suggest a dose-effect relationship: participants taking higher doses of SSRI/SNRI at baseline had a significantly higher risk of fracture.

Authors: Cristiano S. Moura, Sasha Bernatsky, Michal Abrahamowicz et al.

This research was funded by CIHR – Drug Safety and Effectiveness Network and conducted by investigators affiliated with the following institutions:

Link to publication: Moura et al, 2014.